Friedreich’s Ataxia Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) | Key Companies – Reata Pharmaceuticals (SKYCLARYS/Omavaloxolone), AavantiBio, Minoryx, Retrotope

March 01 21:58 2023
Friedreich's Ataxia Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) | Key Companies - Reata Pharmaceuticals (SKYCLARYS/Omavaloxolone), AavantiBio, Minoryx, Retrotope
Delveinsight Business Research LLP
As per DelveInsight, Friedreich’s Ataxia Market is anticipated to grow in the coming years owing to the rise in prevalence and expedited R&D activities of the pharma giants towards developing new drug therapy options to treat Friedreich’s Ataxia. Currently, key players such as Reata Pharmaceuticals (Omaveloxolone), Retrotope (RT001), PTC Therapeutics (Vatiquinone), Minoryx Therapeutics (Leriglitazone), among others, are actively involved in the development of novel therapeutic products.

DelveInsight’s “Friedreich’s Ataxia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Friedreich’s Ataxia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Friedreich’s Ataxia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Friedreich's Ataxia Market

Friedreich’s Ataxia: An Overview

Friedreich ataxia (also called FA) is a rare inherited disease that causes progressive nervous system damage and movement problems. It usually begins in childhood and leads to impaired muscle coordination (ataxia) that worsens over time.

It is caused due to a defect (mutation) in a gene labeled FXN, which carries the genetic code for a protein called frataxin. Therefore, individuals who inherit two defective copies of the gene, one from each parent, will develop the disease. FA is characterized by two subtypes, LOFA and VLOFA. For LOFA, the age of onset is between the ages of 26 and 39 years, and for VLOFA, the age of onset is after the age of 40 years.

On February 28, 2023, Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced that the U.S. Food and Drug Administration (“FDA”) had approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older. With this approval, the FDA granted a rare pediatric disease priority review voucher.

Friedreich’s Ataxia Market Key Facts

  • According to the National Institute of Neurological Disorders and Stroke, Friedreich ataxia is the most common form of hereditary ataxia in the US, affecting about 1 in every 50,000 people.

  • Although classified as a rare disease with a prevalence of 1 in 40,000, FA is the most common inherited ataxia in humans. It imposes a substantially greater burden and stress on patients and families compared with other diseases for both quality of life and expense. Thus, measures are required that can delay the progression of cardiovascular disease, such as HF or arrhythmias, and maintain patient independence and freedom from events such as hospitalizations or emergency department visits.

  • As per the statistics by the National Institute of Neurological Disorders and Stroke, although rare, FA is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people. Adult or late-onset FA is less common, <25% of diagnosed individuals, and can occur anytime during adulthood.

  • According to the study by Jörg S et al. (2009), Friedreich ataxia is the most frequent hereditary ataxia, with an estimated prevalence of 3–4 cases per 100,000 individuals.

Friedreich’s Ataxia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Friedreich’s Ataxia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Friedreich’s Ataxia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Friedreich’s Ataxia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Friedreich’s Ataxia Epidemiology, Segmented as –

  • Total Prevalent Cases of Friedreich’s Ataxia [2019–2032]

  • Diagnosed and Treatable Population of Friedreich’s Ataxia [2019–2032]

  • Prevalence of Friedreich’s Ataxia based on onset types [2019–2032]

Friedreich’s Ataxia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Friedreich’s Ataxia market or expected to be launched during the study period. The analysis covers the Friedreich’s Ataxia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Friedreich’s Ataxia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Friedreich’s Ataxia Market Will Evolve and Grow by 2032 @

Friedreich’s Ataxia Therapeutics Analysis

Several major pharma and biotech giants are actively working in the Friedreich’s Ataxia Market. Currently, Retrotope is leading the therapeutics market with its Friedreich’s Ataxia drug candidates in the most advanced stage of clinical development.

Leading Companies in the Friedreich’s Ataxia Therapeutics Market Include:

  • AavantiBio

  • Design Therapeutics

  • Exicure

  • Lacerta Therapeutics

  • Larimar Therapeutics

  • LEXEO Therapeutics

  • Metro International Biotech

  • Minoryx Therapeutics

  • PTC Therapeutics

  • Reata Pharmaceuticals

  • Retrotope

  • StrideBio

  • Voyager Therapeutics

And Many Others

Friedreich’s Ataxia Emerging and Marketed Drugs Covered in the Report Include:

  • CTI-1601: Larimar Therapeutics

  • FXN gene therapy: AavantiBio

  • Leriglitazone: Minoryx Therapeutics

  • MIB-626: Metro International Biotech

  • Omaveloxolone: Reata Pharmaceuticals

  • RT001: Retrotope

  • SynTEFs: Design Therapeutics

  • Vatiquinone: PTC Therapeutics

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Friedreich’s Ataxia Competitive Intelligence Analysis

4. Friedreich’s Ataxia Market Overview at a Glance

5. Friedreich’s Ataxia Disease Background and Overview

6. Friedreich’s Ataxia Patient Journey

7. Friedreich’s Ataxia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Friedreich’s Ataxia Treatment Algorithm, Current Treatment, and Medical Practices

9. Friedreich’s Ataxia Unmet Needs

10. Key Endpoints of Friedreich’s Ataxia Treatment

11. Friedreich’s Ataxia Marketed Products

12. Friedreich’s Ataxia Emerging Drugs and Latest Therapeutic Advances

13. Friedreich’s Ataxia Seven Major Market Analysis

14. Attribute Analysis

15. Friedreich’s Ataxia Market Outlook (In US, EU5, and Japan)

16. Friedreich’s Ataxia Access and Reimbursement Overview

17. KOL Views on the Friedreich’s Ataxia Market

18. Friedreich’s Ataxia Market Drivers

19. Friedreich’s Ataxia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States